United States Biotechnology & Medical Research

IQVIA Holdings Inc (IQV)

Track

Over the past 90 days, IQVIA Holdings Inc. insiders have executed 11 transactions, all of which were sales totaling approximately $27.5 million in net value. These activities occurred following the company's recent earnings report. The stock has seen a 32.2% price increase over the same period, currently trading near its 52-week high.
Ticker: IQV Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for IQVIA Holdings Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 3 Aug 2026
Value US$1,660,617.76 | Price 193.65 | Shares 52,788 (+16.5%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-04 2026-08-03 S Sale
3.2
STAUB W RICHARD

See Remarks

Officer
52,788 +16.5%
193.65
US$1,660,618 		52,788 +16.5% 193.65 US$1,660,618
2026-08-03 2026-08-03 PrS Proposed sale
3.2
WALTER STAUB

Officer

Officer
20,435
445.11
US$457,772 		20,435 445.11 US$457,772
2026-08-04 2026-07-31 S Sale
Patel Bhavik

See Remarks

Officer
58,741 +41.2%
187.02
US$2,027,281 		58,741 +41.2% 187.02 US$2,027,281
2026-07-31 2026-07-31 PrS Proposed sale
BHAVIK PATEL

Officer

Officer
1,000
235.27
US$100,000 		1,000 235.27 US$100,000
2026-07-31 2026-07-29 S Sale
2.7
Sherbet Eric

See Remarks

Officer
1,000 -19.2%
249.16
US$100,000 		1,000 -19.2% 249.16 US$100,000
2026-07-31 2026-07-29 S Sale
1.3
Cherofsky Keriann

See Remarks

Officer
1,000 -15.7%
245.21
US$100,000 		1,000 -15.7% 245.21 US$100,000
2026-07-31 2026-07-29 S Sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
1,000 -5.7%
244.78
US$100,000 		1,000 -5.7% 244.78 US$100,000
2026-07-31 2026-07-29 S Sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
1,000 -4.5%
246.08
US$100,000 		1,000 -4.5% 246.08 US$100,000
2026-07-31 2026-07-29 S Sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
1,000 -0.5%
246.85
US$100,000 		1,000 -0.5% 246.85 US$100,000
2026-07-31 2026-07-29 S Sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
1,000 -0.5%
247.10
US$100,000 		1,000 -0.5% 247.10 US$100,000
2026-07-29 2026-07-29 PrS Proposed sale
1.3
KERIANN CHEROFSKY

Officer

Officer
1,000
245.21
US$100,000 		1,000 245.21 US$100,000
2026-07-29 2026-07-29 PrS Proposed sale
2.7
ERIC SHERBET

Officer

Officer
1,000
249.16
US$100,000 		1,000 249.16 US$100,000
2026-07-29 2026-07-29 PrS Proposed sale
3.4
ARI BOUSBIB

Officer; Director

Executive Director
1,000
245.50
US$100,000 		1,000 245.50 US$100,000
2025-12-19 2025-12-18 S Sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
36,564 -4.3%
222.43
US$8,132,931 		36,564 -4.3% 222.43 US$8,132,931
2025-12-18 2025-12-18 PrS Proposed sale
3.4
ARI BOUSBIB

Officer; Director

Executive Director
36,564
222.43
US$8,132,876 		36,564 222.43 US$8,132,876
2025-10-31 2025-10-29 S Sale
2.7
Sherbet Eric

See Remarks

Officer
4,000 -12.9%
219.70
US$878,800 		4,000 -12.9% 219.70 US$878,800
2025-10-31 2025-10-29 S Sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
3,973 -0.5%
221.97
US$881,887 		3,973 -0.5% 221.97 US$881,887
2025-10-31 2025-10-29 S Sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
26,128 -3.0%
221.31
US$5,782,388 		26,128 -3.0% 221.31 US$5,782,388
2025-10-31 2025-10-29 S Sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
4,600 -0.5%
220.11
US$1,012,506 		4,600 -0.5% 220.11 US$1,012,506
2025-10-31 2025-10-29 S Sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
13,741 -1.6%
219.29
US$3,013,264 		13,741 -1.6% 219.29 US$3,013,264
2025-10-31 2025-10-29 S Sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
7,315 -0.8%
218.32
US$1,597,011 		7,315 -0.8% 218.32 US$1,597,011
2025-10-31 2025-10-29 S Sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
800 -0.1%
217.58
US$174,064 		800 -0.1% 217.58 US$174,064
2025-10-29 2025-10-29 PrS Proposed sale
3.4
ARI BOUSBIB

Officer; Director

Executive Director
56,557
220.33
US$12,460,983 		56,557 220.33 US$12,460,983
2025-10-29 2025-10-29 PrS Proposed sale
2.7
ERIC SHERBET

Officer

Officer
4,000
219.70
US$878,820 		4,000 219.70 US$878,820
2025-07-25 2025-07-23 S Sale
1.3
Cherofsky Keriann

See Remarks

Officer
549 -15.9%
191.53
US$105,150 		549 -15.9% 191.53 US$105,150
2025-07-25 2025-07-23 S Sale
2.7
Sherbet Eric

See Remarks

Officer
5,800 -17.6%
190.05
US$1,102,290 		5,800 -17.6% 190.05 US$1,102,290
2025-07-23 2025-07-23 PrS Proposed sale
2.7
ERIC SHERBET

Officer

Officer
5,800
190.05
US$1,102,262 		5,800 190.05 US$1,102,262
2025-07-23 2025-07-23 PrS Proposed sale
1.3
KERIANN CHEROFSKY

Officer

Officer
549
191.53
US$105,150 		549 191.53 US$105,150
2025-02-07 2024-12-03 B Purchase DANHAKL JOHN G Non-Executive Director
1,275 +inf%
200.58
US$255,740 		1,275 +inf% 200.58 US$255,740
2024-08-29 2024-08-27 S Sale
2.7
Sherbet Eric

See Remarks

Officer
1,300 -6.2%
246.33
US$320,229 		1,300 -6.2% 246.33 US$320,229
2024-08-27 2024-08-27 PrS Proposed sale
2.7
Sherbet Eric

Officer

Officer
1,300
246.33
US$320,229 		1,300 246.33 US$320,229
2024-03-04 2024-03-01 S Sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
15,417 -1.9%
251.03
US$3,870,130 		15,417 -1.9% 251.03 US$3,870,130
2024-03-04 2024-03-01 S Sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
16,261 -2.0%
250.05
US$4,066,063 		16,261 -2.0% 250.05 US$4,066,063
2024-03-01 2024-03-01 PrS Proposed sale
3.4
BOUSBIB ARI

Officer

Officer
31,678
247.16
US$7,829,534 		31,678 247.16 US$7,829,534
2024-03-04 2024-02-29 S Sale
3.2
STAUB W RICHARD

See Remarks

Officer
2,068 -11.5%
249.08
US$515,097 		2,068 -11.5% 249.08 US$515,097
2024-03-04 2024-02-29 S Sale
3.2
STAUB W RICHARD

See Remarks

Officer
3,062 -14.5%
248.33
US$760,386 		3,062 -14.5% 248.33 US$760,386
2024-03-04 2024-02-29 S Sale
3.2
STAUB W RICHARD

See Remarks

Officer
8,970 -29.9%
247.33
US$2,218,550 		8,970 -29.9% 247.33 US$2,218,550
2024-02-29 2024-02-29 PrS Proposed sale
3.2
STAUB W RICHARD

Officer

Officer
14,100
234.76
US$3,310,116 		14,100 234.76 US$3,310,116
2024-03-01 2024-02-28 S Sale
3.1
Knightly Kevin C

See Remarks

Officer
2,182 -29.4%
250.83
US$547,311 		2,182 -29.4% 250.83 US$547,311
2024-03-01 2024-02-28 S Sale
3.1
Knightly Kevin C

See Remarks

Officer
6,425 -46.4%
249.94
US$1,605,864 		6,425 -46.4% 249.94 US$1,605,864
2024-02-28 2024-02-28 PrS Proposed sale
3.1
Knightly Kevin C

Officer

Officer
8,607
238.60
US$2,053,630 		8,607 238.60 US$2,053,630
2024-02-21 2024-02-16 S Sale
2.7
Sherbet Eric

See Remarks

Officer
1,000 -4.6%
241.50
US$241,500 		1,000 -4.6% 241.50 US$241,500
2024-02-21 2024-02-16 S Sale
3.1
Knightly Kevin C

See Remarks

Officer
4,021 -86.0%
241.38
US$970,589 		4,021 -86.0% 241.38 US$970,589
2024-02-21 2024-02-16 S Sale
3.1
Knightly Kevin C

See Remarks

Officer
1,239 -21.0%
240.73
US$298,264 		1,239 -21.0% 240.73 US$298,264
2024-02-21 2024-02-16 S Sale
3.1
Knightly Kevin C

See Remarks

Officer
4,867 -33.1%
241.23
US$1,174,066 		4,867 -33.1% 241.23 US$1,174,066
2024-02-21 2024-02-16 S Sale
3.1
Knightly Kevin C

See Remarks

Officer
3,341 -18.5%
240.72
US$804,246 		3,341 -18.5% 240.72 US$804,246
2024-02-16 2024-02-16 PrS Proposed sale
2.7
Sherbet Eric

Officer

Officer
1,000
241.50
US$241,500 		1,000 241.50 US$241,500
2024-02-16 2024-02-16 PrS Proposed sale
3.1
Knightly Kevin C

Officer

Officer
13,468
214.34
US$2,886,731 		13,468 214.34 US$2,886,731
2023-12-05 2023-12-01 S Sale
3.1
Knightly Kevin C

See Remarks

Officer
378 -4.9%
215.29
US$81,380 		378 -4.9% 215.29 US$81,380
2023-12-05 2023-12-01 S Sale
3.1
Knightly Kevin C

See Remarks

Officer
5,855 -43.1%
214.32
US$1,254,844 		5,855 -43.1% 214.32 US$1,254,844
2023-12-05 2023-12-01 S Sale
3.1
Knightly Kevin C

See Remarks

Officer
6,884 -33.6%
213.72
US$1,471,248 		6,884 -33.6% 213.72 US$1,471,248
2023-12-01 2023-12-01 PrS Proposed sale
3.1
Knightly Kevin C

Officer

Officer
13,117
210.73
US$2,764,145 		13,117 210.73 US$2,764,145
2023-09-21 2023-09-19 S Sale
1.7
Panagos Constantinos

See Remarks

Officer
7,419 -18.3%
208.63
US$1,547,826 		7,419 -18.3% 208.63 US$1,547,826
2023-09-21 2023-09-19 S Sale
1.7
Panagos Constantinos

See Remarks

Officer
19,898 -58.3%
208.69
US$4,152,514 		19,898 -58.3% 208.69 US$4,152,514
2023-09-19 2023-09-19 PrS Proposed sale
1.7
Panagos Constantinos

Officer

Officer
27,317
209.35
US$5,718,814 		27,317 209.35 US$5,718,814
2023-06-07 2023-06-05 S Sale
3.1
Knightly Kevin C

See Remarks

Officer
5,820 -100.0%
201.89
US$1,175,000 		5,820 -100.0% 201.89 US$1,175,000
2023-05-31 2023-05-26 S Sale
3.1
Knightly Kevin C

See Remarks

Officer
1 -100.0%
198.66
US$199 		1 -100.0% 198.66 US$199
2023-05-25 2023-05-25 PrS Proposed sale
3.1
Knightly Kevin C

Officer

Officer
5,821
198.03
US$1,152,732 		5,821 198.03 US$1,152,732
2023-02-17 2023-02-16 S Sale
3.1
Knightly Kevin C

See Remarks

Officer
2,772 -58.4%
225.57
US$625,280 		2,772 -58.4% 225.57 US$625,280
2023-02-17 2023-02-16 S Sale
3.1
Knightly Kevin C

See Remarks

Officer
1,674 -26.1%
225.68
US$377,788 		1,674 -26.1% 225.68 US$377,788
2023-02-15 2023-02-14 S Sale
2.7
Sherbet Eric

See Remarks

Officer
1,000 -5.5%
230.00
US$230,000 		1,000 -5.5% 230.00 US$230,000
2021-12-23 2021-12-22 B Purchase
3.1
DANHAKL JOHN G
Non-Executive Director
10,000 +69.7%
272.93
US$2,729,300 		10,000 +69.7% 272.93 US$2,729,300
2021-12-01 2021-11-29 S Sale
3.4
CONNAUGHTON JOHN
Non-Executive Director
555,094 -89.9%
262.60
US$145,767,684 		555,094 -89.9% 262.60 US$145,767,684
2022-02-17 2021-10-25 S Sale
2.8
Bruehlman Ronald E

See Remarks

Officer
4 -0.0%
256.93
US$1,028 		4 -0.0% 256.93 US$1,028
2022-02-17 2021-09-23 B Purchase
2.8
Bruehlman Ronald E

See Remarks

Officer
4 +0.0%
262.82
US$1,051 		4 +0.0% 262.82 US$1,051
2022-02-14 2021-07-20 B Purchase
2.8
Bruehlman Ronald E

See Remarks

Officer
13 +0.1%
245.32
US$3,189 		13 +0.1% 245.32 US$3,189
2020-12-28 2020-12-23 B Purchase
3.1
DANHAKL JOHN G
Non-Executive Director
63,451 +85.8%
176.95
US$11,227,654 		63,451 +85.8% 176.95 US$11,227,654
2020-11-25 2020-11-24 S Sale
3.3
Rittenmeyer Ronald A
Non-Executive Director
9,590 -44.6%
172.96
US$1,658,686 		9,590 -44.6% 172.96 US$1,658,686
2020-11-18 2020-11-16 S Sale
3.3
Rittenmeyer Ronald A
Non-Executive Director
40,792 -65.5%
174.35
US$7,112,085 		40,792 -65.5% 174.35 US$7,112,085
2020-10-14 2020-10-12 PlS Planned sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
69,120 -9.6%
170.00
US$11,750,400 		69,120 -9.6% 170.00 US$11,750,400
2020-09-17 2020-09-15 PlS Planned sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
46,080 -6.6%
164.36
US$7,573,709 		46,080 -6.6% 164.36 US$7,573,709
2020-08-18 2020-08-14 PlS Planned sale
3.4
BOUSBIB ARI

See Remarks

Executive Director
69,120 -9.6%
161.66
US$11,173,939 		69,120 -9.6% 161.66 US$11,173,939
2020-08-11 2020-08-07 S Sale
3.2
STAUB W RICHARD

See Remarks

Officer
6,884 -20.9%
160.04
US$1,101,715 		6,884 -20.9% 160.04 US$1,101,715
2020-08-11 2020-08-07 S Sale
3.2
STAUB W RICHARD

See Remarks

Officer
13,483 -52.0%
160.47
US$2,163,617 		13,483 -52.0% 160.47 US$2,163,617
2020-08-05 2020-08-04 B Purchase
2.8
Bruehlman Ronald E

See Remarks

Officer
10,000 +59.7%
159.94
US$1,599,400 		10,000 +59.7% 159.94 US$1,599,400
Explore more

More insider trading research around IQVIA Holdings Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America
Insider trades in S&P 500